UNSPSC 51294909: Dosulepin hydrochloride

This classification denotes an antidepressant agent with the molecular formula C19H21NS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3H0042311V, chemically known as 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepine hydrochloride but more generally known as dosulepin hydrochloride, which bears US NIH Compound Identifier 5282425. European Medicines Agency schedules Dosulepin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01821MIG.

Most nations, for tariff and trade purposes, schedule dosulepin hydrochloride under HS 29349990 and SITC 51579. SMILES: CN(C)CC/C=C/1\C2CCCCC2CSC3C1CCCC3.CL.

UNSPSC 51294909 Dosulepin hydrochloride is a Commodity code that does not align with the recent state and local opportunities tagged under it. The three most recent opportunities—a Seminole County naloxone and drug deactivation systems procurement, a Texas HHS direct-to-manufacturer prescription program RFI, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic pharmaceuticals and OTC products RFP—address naloxone supply, prescription fulfillment models, and multi-source generic drug contracting, respectively. None of these solicitations reference dosulepin hydrochloride or antidepressant medications specifically. The code shows little relevant recent activity in the state and local procurement record.

The tagged opportunities themselves span diverse issuing bodies and procurement stages: Seminole County, Florida (a county health agency issuing a competitive IFB for naloxone and drug deactivation systems with a July 26, 2023 response deadline); the Texas Health and Human Services Commission (a state agency issuing an RFI on March 27, 2026 with an April 3, 2026 response deadline to explore direct-to-manufacturer prescription contracting); and MMCAP administered by the Minnesota Department of Administration (a multistate cooperative purchasing vehicle issuing an RFP with a March 26, 2026 response deadline for generic pharmaceuticals across state and local facilities in Minnesota and Oregon). The mismatch between the dosulepin hydrochloride code designation and the actual scope of these opportunities suggests either miscoding at posting or a data quality issue that limits the code's utility for tracking genuine antidepressant medication procurement at the state and local level.